Lipid Changes in Early Alzheimer's Disease
Author Information
Author(s): Han Xianlin, Rozen Steve, Boyle Stephen H., Hellegers Caroline, Cheng Hua, Burke James R., Welsh-Bohmer Kathleen A., Doraiswamy P. Murali, Kaddurah-Daouk Rima
Primary Institution: Duke University Medical Center
Hypothesis
The plasma lipidome is altered in early Alzheimer's disease.
Conclusion
The study found significant reductions in sphingomyelin levels and increases in ceramide levels in the plasma of Alzheimer's disease patients compared to controls.
Supporting Evidence
- Plasma levels of sphingolipids were significantly altered in Alzheimer's disease.
- Eight sphingomyelin species were significantly lower in AD patients compared to controls.
- Two ceramide species were significantly higher in AD patients.
- MMSE scores correlated with altered mass levels of specific sphingolipids.
- Ratios of ceramide to sphingomyelin species differed significantly between AD patients and controls.
Takeaway
This study looked at blood samples from people with Alzheimer's disease and found that certain fats in their blood were different from those without the disease, which might help in early diagnosis.
Methodology
The study used multi-dimensional mass spectrometry-based shotgun lipidomics to analyze plasma samples from Alzheimer's patients and cognitively normal controls.
Potential Biases
Possible biases from differences in age, diet, medical status, and concomitant medications among participants.
Limitations
The study had a small sample size and potential biases due to participant selection and other confounding factors.
Participant Demographics
26 Alzheimer's patients and 26 cognitively normal controls, with a mean age of 77.2 for AD patients and 73.0 for controls.
Statistical Information
P-Value
p<0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website